L-Proline, 1-ethyl-5-oxo- | 950749-08-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Proline, 1-ethyl-5-oxo-
• 英文别名: (2S)-1-ethyl-5-oxopyrrolidine-2-carboxylic acid
• CAS: 950749-08-3
• 化学式: C₇H₁₁NO₃
• 分子量: 157.169
• InChiKey: AGWPBFFUIGQGJG-YFKPBYRVSA-N

物化性质

• 沸点：
  363.1±35.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-Proline, 1-ethyl-5-oxo- 、 3-氯苄胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-N-[(3-chlorophenyl)methyl]-1-ethyl-5-oxopyrrolidine-2-carboxamide
  参考文献：
  名称：

  Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

  摘要：

  A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.033
• 作为产物：
  描述：

  Methyl (2S)-1-ethyl-5-oxopyrrolidine-2-carboxylate 在 甲醇 、 水 、 sodium hydroxide 作用下， 生成 L-Proline, 1-ethyl-5-oxo-
  参考文献：
  名称：

  Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

  摘要：

  A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.033

文献信息

• [EN] 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS<br/>[FR] CARBOXAMIDES DE 3,7-DIAZABICYCLO[3.3.1]NONANE À TITRE D'AGENTS ANTITHROMBOTIQUES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015044951A1

  公开（公告）日：2015-04-02

  The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

  本发明涉及3,7-二氮杂双环[3.3.1]壬烷羧酰胺及其制备方法。本发明还涉及具有抗血栓（抗血小板）活性的一般式（1）化合物。该发明还涉及将这些基团用作体外和体内介导的胶原受体抑制剂，抑制胶原诱导的血小板粘附和聚集。此外，该发明还涉及这类化合物通过双重机制表现出抗血小板功效，既抑制了胶原又抑制了U46619（血栓素受体激动剂）诱导的血小板聚集。一般式（1）中，其中，R'为；其中R选自烷基、酰基、对甲苯磺酰基、叔丁氧羰基、芳基烷基或取代芳基烷基；R''优选选自卤素、氰基、低烷基、芳基、取代芳基和对甲苯磺基；R1选自氢和低烷基；R2选自低烷基和芳基；R3选自叔丁氧羰基和苯甲氧羰基；n = 0,1。
• Novel Receptor Antagonists and Their Methods of Use
  申请人：Chambers J. Laura

  公开号：US20080009541A1

  公开（公告）日：2008-01-10

  The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及一种新型的氧代脯氨酰胺衍生物，其化学式为（I），可以调节P2X7受体功能，并能够拮抗P2X7受体上ATP的作用，以及利用这些化合物或其药物组合物治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性疾病。
• [EN] IMPROVED PROCESS FOR THE PREPARATION OF (2S)-N-{(1S)-1-(2-CHLOROPHENYL)-2-[(3,3-DIFLUOROCYCLOBUTYL)-AMINO]-2-OXOETHYL}-1-(4-CYANOPYRIDIN-2-YL)-N-(5-FLUOROPYRIDIN-3-YL)-5-OXOPYRROLIDINE-2-CARBOXAMIDE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE (2S)-N-{(1S)-1-(2-CHLOROPHÉNYL)-2-[(3,3-DIFLUOROCYCLOBUTYL)-AMINO]-2-OXOÉTHYL}-1-(4-CYANOPYRIDIN-2-YL)-N-(5-FLUOROPYRIDIN-3-YL)-5-OXOPYRROLIDINE-2-CARBOXAMIDE
  申请人：MSN LABORATORIES PRIVATE LTD R&D CENTER

  公开号：WO2021079380A1

  公开（公告）日：2021-04-29

  The present invention relates to improved process for the preparation of (2S)-N-(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide and its pharmaceutically acceptable salts represented by the following structural formula. Formula-1 The present invention relates to novel intermediates useful in the preparation of Ivosidenib of formula-1 and novel process for the preparation of (2S)-N-(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2­oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide. The present invention also relates to solid state forms of (2S)-N-(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2­ oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide.

  本发明涉及改进的制备过程，用于制备(2S)-N-(1S)-1-(2-氯苯基)-2-[(3,3-二氟环丁基)-氨基]-2-氧乙基}-1-(4-氰吡啶-2-基)-N-(5-氟吡啶-3-基)-5-氧吡咯啉-2-羧酰胺及其在以下结构式中表示的药用盐。 结构式-1 本发明涉及在制备结构式-1的Ivosidenib中有用的新中间体以及用于制备(2S)-N-(1S)-1-(2-氯苯基)-2-[(3,3-二氟环丁基)-氨基]-2-氧乙基}-1-(4-氰吡啶-2-基)-N-(5-氟吡啶-3-基)-5-氧吡咯啉-2-羧酰胺的新方法。 本发明还涉及(2S)-N-(1S)-1-(2-氯苯基)-2-[(3,3-二氟环丁基)-氨基]-2-氧乙基}-1-(4-氰吡啶-2-基)-N-(5-氟吡啶-3-基)-5-氧吡咯啉-2-羧酰胺的固态形式。
• [EN] HYPERPOLARIZED ESTERS AS METABOLIC MARKERS IN MR<br/>[FR] ESTERS HYPERPOLARISÉS UTILISÉS EN TANT QUE MARQUEURS MÉTABOLIQUES EN RM
  申请人：BRACCO IMAGING SPA

  公开号：WO2014118258A1

  公开（公告）日：2014-08-07

  The invention relates to a method of Magnetic Resonance (MR) detection, in particular 13C-MR detection, by using a diagnostic medium comprising a hyperpolarized ester, in particular ethyl acetoacetate. The method comprises the detection of the MR signal of a hyperpolarized 13C carboxylic ester and of its respective hyperpolarized metabolite.

  本发明涉及使用一种诊断介质，其中包括一个超极化酯，特别是乙酰乙酸乙酯，通过使用磁共振（MR）检测方法，特别是13C-MR检测方法进行检测。该方法包括检测超极化13C羧酸酯及其相应的超极化代谢物的MR信号。
• Process for synthesizing L--methylene glutamic acid and analogs
  申请人：——

  公开号：US20040106826A1

  公开（公告）日：2004-06-03

  A process for synthesizing substantially enantiomerically pure L-amino acids, particularly L- -methylene glutamic acid, and esters and salts thereof. The process includes the derivatization of (2S)-pyroglutamic acid, and the decyclization of the resulting derivative to form the desired end product.

  一种合成基本对映纯L-氨基酸的方法，特别是L- -亚甲基谷氨酸及其酯和盐的方法。该方法包括对(2S)-吡咯烷酸进行衍生化，以及对所得衍生物进行去环化反应，形成所需的最终产物。